Fighting Cancer

Every Step of the Way

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit
vb-homepage-image3

Dedicated to Early Intervention. And Life.


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Its OncAlert™ Oral Cancer System uses patented technology that is highly-accurate and specific.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences’ products are based on patented technology that detects specific protein markers known to clinically show elevated risk for early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or Lab

Both the rapid point-of-care test and the lab assay that comprise the OncAlert™ System provide a timely, accurate, and specific risk assessment for oral cancer... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • vb-400x210

    Vigilant Biosciences to Present at the Biotech Showcase™ 2016

    FORT LAUDERDALE, Fla. – Jan. 6, 2016 – Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that Matthew Kim, Founder, Chairman and CEO of Vigilant…more

  • Seeing the Unseen: Oral Cancer Risk Assessment: Past Present and Future

    by John C. Comisi, DDS, MAGD Oral Squamous Cell Carcinoma (OSCC) and Head and Neck Squamous Cell Carcinoma (HNSCC) have confounded the health care profession for a great length of time. A deadly and costly disease, the profession is still…more

  • dentistry-today

    Cancer Detection Tool Earns CE Mark

    The OncAlert Oral Cancer CD44/Total Protein LAB Test from Vigilant Biosciences now has the CE Mark, which means it has been approved for distribution and marketing in the 28 countries of the European Union (EU) as well as in Norway,…more

  • vb-400x210

    Vigilant Biosciences Selects Cardinal Health as Global Third Party Logistics Provider for OncAlert(TM) Oral Cancer System

    FORT LAUDERDALE, Fla. – November 18, 2015 – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it has selected Cardinal Health, Inc., a leading healthcare…more


©2011-2016 Vigilant Biosciences, Inc. All Rights Reserved.

×